linkedin

Press Releases

Press Releases

Samsung Biologics completes full acquisition of Samsung Bioepis

COMPANY NEWS

COMPANY NEWS

Samsung Biologics completes full acquisition of Samsung Bioepis

 

  Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary

  First payment completed funded through paid in capital  

  Accelerated growth expected in biosimilars and future novel therapeutics R&D

 

Incheon, S. Korea, April 20, 2022 – Samsung Biologics (KRX: 207940.KS) announced today that it has completed the purchase of Biogen’s stake in the Samsung Bioepis joint venture for USD $2.3 billion. With the completion of the first payment of USD $1.0 billion pursuant to the terms of the acquisition agreement, Samsung Biologics has now fully acquired Samsung Bioepis as a wholly owned subsidiary. The remaining USD $1.3 billion will be made in installments over two years.

 

“Today’s announcement marks a significant milestone for Samsung Biologics in our continued venture into the biosimilar business and accelerating biosimilar growth,” said John Rim, CEO and President of Samsung Biologics. “By leveraging our extensive experience as a leading CDMO, we will further contribute to saving lives of the patients and address a wide array of diseases.” 

 

The purchase was funded by a portion of paid-in capital increase of KRW 3 trillion (approximately USD $2.5 billion) raised by issuing new shares, the proceeds of which will be used to fund the company’s strategic growth plans.  The acquisition gives Samsung Bioepis improved autonomy and agility in business operations, accelerating sales growth, operating margin improvements, as well as biosimilar development capabilities and future performance in novel drug development. 

 

Samsung Biologics will continue to deliver on its commitment to clients and shareholders by providing quality-driven CDMO biomanufacturing services. The company is currently building Plant 4, which will partially become operational in October 2022. In addition, Samsung Biologics is in the process of securing additional land of 350,000m2 for Bio Campus II, which will be 30% larger than the size of the current site for future growth.

 

 COMPANY NEWS

COMPANY NEWS

Samsung Biologics completes full acquisition of Samsung Bioepis

 

  Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary

  First payment completed funded through paid in capital  

  Accelerated growth expected in biosimilars and future novel therapeutics R&D

 

Incheon, S. Korea, April 20, 2022 – Samsung Biologics (KRX: 207940.KS) announced today that it has completed the purchase of Biogen’s stake in the Samsung Bioepis joint venture for USD $2.3 billion. With the completion of the first payment of USD $1.0 billion pursuant to the terms of the acquisition agreement, Samsung Biologics has now fully acquired Samsung Bioepis as a wholly owned subsidiary. The remaining USD $1.3 billion will be made in installments over two years.

 

“Today’s announcement marks a significant milestone for Samsung Biologics in our continued venture into the biosimilar business and accelerating biosimilar growth,” said John Rim, CEO and President of Samsung Biologics. “By leveraging our extensive experience as a leading CDMO, we will further contribute to saving lives of the patients and address a wide array of diseases.” 

 

The purchase was funded by a portion of paid-in capital increase of KRW 3 trillion (approximately USD $2.5 billion) raised by issuing new shares, the proceeds of which will be used to fund the company’s strategic growth plans.  The acquisition gives Samsung Bioepis improved autonomy and agility in business operations, accelerating sales growth, operating margin improvements, as well as biosimilar development capabilities and future performance in novel drug development. 

 

Samsung Biologics will continue to deliver on its commitment to clients and shareholders by providing quality-driven CDMO biomanufacturing services. The company is currently building Plant 4, which will partially become operational in October 2022. In addition, Samsung Biologics is in the process of securing additional land of 350,000m2 for Bio Campus II, which will be 30% larger than the size of the current site for future growth.

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved